BIIB095
Phase 1Small molecule
BiogenBIIB095 is one of 20 small molecule programs targeting Diabetic Polyneuropathy. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Diabetic Polyneuropathy
#DrugCompanyPhaseTrials
1Oxycontin
PProtega
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Narcan
SScienture
Approved
Adenosine Triphosphate
EEgyptian International Pharmaceutical Industries Co
Approved
Alpha-Lipoic Acid (ALA)
EEva Pharma
Approved
Crestor
AstraZenecaPhase 2
Thioctic Acid
MMEDA Pharma GmbH & Co. KG
Phase 3
DLBS1033
DDexa Medica Group
Phase 3
Vyepti
LundbeckPhase 2
Adezunap
AApurano Pharmaceuticals GmbH
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BIIB095. EMBL-EBI & Wellcome Sanger Institute.
- [4]